Address: Insure Insights 61 Bridge Street, Kington.HR5 3DJ United Kingdom

Global RNAi Technology Market Outlook 2020: Global Opportunity and Demand Analysis, Market Forecast, 2019-2028

  • Home
  • Reports
  • Global RNAi Technology Market Outlook 2020: Global Opportunity and Demand Analysis, Market Forecast, 2019-2028
Global RNAi Technology Market Outlook 2020: Global Opportunity and Demand Analysis, Market Forecast, 2019-2028

Global RNAi Technology Market Outlook 2020: Global Opportunity and Demand Analysis, Market Forecast, 2019-2028

  • Published Date: 30 Jun 2021
  • Report ID: HLT 00230
  • Pages: 178
  • Base Year: 2019
  • Format: PDF
  • Historical Data: 2016-2019

RNAi Technology is anticipated to have CAGR of ~10.5% over 2019-2028. The key factor that would aid in the market growth includes the growth in demand for efficient therapeutics for chronic and acute conditions. The surge in the number of applications of the RNAi technology in molecular diagnostics, especially in the cancer disease is expected to help the industry gain lucrative growth. Furthermore, the improvement in the synthetic delivery carriers and chemical modifications are anticipated to contribute to a significant growth, during the forecast period. The surge in the number of infections would propel the industry. However, the increase in the government regulations over the use of such technology may hamper the market growth.

Top Driver: Growth in the applications to boost the industry

RNAi Technology is projected to grow with the widening of the applications of the RNAi technology in the coming years. RNAi technology enabled every gene in the human genome to serve as a druggable target.  This is anticipated to create new opportunities for various vendors to develop a comparatively wider range of targeted therapies. Furthermore, this would help attract many drug manufacturers to invest over the development of RNAi-based targeted cancer therapies. There are several early-phase trials, which have reported crucial clinical responses in the case of RNAi therapies and also directed against targets, especially Kinesin spindle protein (KSP) and vascular endothelial growth factor (VEGF). Henceforth, the rising adoption of RNAi technology for undruggable targets is anticipated to propel the market growth in near future.

Oncology to Make Crucial Contribution to Growth of Global RNAi Technology Market

Among therapeutics segments of the global RNAi Technology market, oncology segment is attributed to gain highest revenue shares in the forecast period. Owing to the surge in the investment over development of the technology to treat cancer patients would propel the industry. The efficacy of the technology over the cancer disease coupled with the surge in the patient population would contribute the market to grow significantly in the coming years. The recent advancements, mainly the development of small interfering RNA (siRNA) tolerant to nucleases and the advancement, development of non-viral vectors would help overcome this obstacle and would ease the clinical use of RNAi-based therapeutics in the treatment of cancer. Respiratory Disorders segment is anticipated to gain highest CAGR due to the rise in the patient population and hence would fuel the industry in the next few years.

Surge in healthcare expenditure to Benefit North America Market

North America is experiencing highest revenue growth than any other country and is anticipated to boost further in the coming years. This owes to the growth in the healthcare expenditure coupled with the rise in the awareness programs offered by the government to help maintain better quality of life would help the industry grow at a lucrative pace in the forecast period. The increase in investments on the R&D of the products would help the industry grow further in the near future. Asia-Pacific region is anticipated to experience highest CAGR due to the surge in the patient population coupled with the growth in the awareness regarding the severity of the diseases.

Due to outbreak of COVID-19 the RNAi Technology has observed the highest growth rate in the current scenario. The increase in the Research and development over the treatment alternatives for the disease would help the industry have a lucrative growth in the coming years.

Players to Focus on RNAi Technology

The global RNAi Technology market leaders include Alnylam Pharmaceuticals, Benitec Biopharma Ltd., Ionis Pharmaceuticals, Horizon Discovery Group Plc, Quark Pharmaceuticals Inc., RXI Pharmaceuticals, Arbutus Biopharma Corp., Arrowhead Pharmaceuticals Inc., Bio-Rad Laboratories Inc., Dicerna Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd., Merck KGaA, QIAGEN NV, and Thermo Fisher Scientific Inc.

Alnylam Pharmaceuticals: In April 2020, Blackstone announced it had invested up to $2bn in Alnylam Pharmaceuticals, which is a pioneer in the field of RNA interference (RNAi) medicines across a wide range of disease areas. The aim is to allow Alnylam to achieve a sustainable financial profile without the need for further equity financing in the future, as well as support the research and development (R&D) and commercialisation of promising RNAi medicines to at-need patients.

Benitec Biopharma Inc.: In April 2020, Benitec Biopharma Inc. announced the previously announced transaction to redomicile from Australia to the United States has been fully implemented. The redomiciliation was approved by Benitec shareholders at a Scheme Meeting held on March 26, 2020, and confirmed by the Supreme Court of Queensland on March 30, 2020.

Ionis Pharmaceuticals, Inc.: In April 2017, Ionis Pharmaceuticals, Inc. announced a collaboration and license agreement with Suzhou Ribo Life Science Co., Ltd. (Ribo) to develop and commercialize RNA-targeted therapeutics in China. Ionis granted Ribo a license for the right to commercialize in China two Ionis Generation 2+ antisense drugs in metabolic disease and cancer and an option to license a third pre-specified Generation 2+ antisense drug.

Scope of the Report

By Application

  • Drug discovery and development
  • Therapeutics
  • Others

By Therapeutics

  • Oncology
  • Ocular disorders
  • Respiratory disorders
  • Liver diseases
  • Neuronal disorders

By Region

  • North America
  • Europe
  • Asia Pacific
  • LAMEA

Key Reasons to Purchase this Report

  1. It provides a technological development map over time to understand the growth rate of the industry.
  2. The report offers a dynamic method to various factors that drive or restrain the growth of the market.
  3. It renders definite analysis for changing competitive dynamics.
  4. It builds a seven-year estimate based on how the market is predicted to grow.

Table of Content

Chapter 1           Overview And Scope

1.1             Market Vision

1.1.1          Market Definition

1.1.2          Market Scope

1.2             Market Segmentation

Chapter 2           Our Research Practice

2.1             Our Research Methodology

2.2             Data Triangulation

2.3             Data Sources

2.4             Assumptions for the study

2.5             Approach Adopted

Chapter 3           Executive Summary

3.1             Market Snapshot

3.2             Regional Snapshot

3.3             Segment Summary

Chapter 4           Covid-19 Impact Analysis

4.1             Overview

4.2             Prevalence analysis

4.3             Key Factor Impact Analysis

Chapter 5           Global Sepsis Diagnostic Market Forces

5.1             What’s Driving the Market

5.2             Porter’s Five Forces Analysis

5.2.1          Power of Suppliers

5.2.2          Threats From New Entrants

5.2.3          Power of Buyer

5.2.4          Threat From Substitute Product

5.2.5          Degree of Competition

Chapter 6           Global Sepsis Diagnostic Market -Industry Snapshots

6.1             Overview

6.1.1          Global Sepsis Diagnostic Market Value, 2019 – 2028, (US$ Bn)

6.2             Market Overview

6.2.1          Drivers Analysis

6.2.2          Restraint/Challenges analysis

6.2.3          Opportunity Analysis

6.3             Supply Chain/Value Chain Analysis

6.4             Market SWOT Analysis

Chapter 7           Global Sepsis Diagnostic Market Analysis, by Technology

7.1             Overview

7.2             Key Findings for Sepsis Diagnostic Market- By Technology

7.2.1          Sepsis Diagnostic Market- Molecular diagnostic

7.2.2          Sepsis Diagnostic Market- Immunoassay

7.2.3          Sepsis Diagnostic Market- Microbiology

7.2.4          Sepsis Diagnostic Market- Others

Chapter 8           Global Sepsis Diagnostic Market Analysis, by Product

8.1             Overview

8.2             Key Findings for Sepsis Diagnostic Market- By Product

8.2.1          Sepsis Diagnostic Market- Instruments

8.2.2          Sepsis Diagnostic Market- Assay kits

8.2.3          Sepsis Diagnostic Market- Blood culture media

8.2.4          Sepsis Diagnostic Market- Others

Chapter 9           Global Sepsis Diagnostic Market Analysis, by Diagnostic method

9.1             Overview

9.2             Key Findings for Sepsis Diagnostic Market- By Diagnostic method

9.2.1          Sepsis Diagnostic Market- Laboratory testing

9.2.2          Sepsis Diagnostic Market- PoC testing

Chapter 10       Global Sepsis Diagnostic Market Analysis, by Pathogen

10.1           Overview

10.2           Key Findings for Sepsis Diagnostic Market- By Pathogen

10.2.1       Sepsis Diagnostic Market- Fungal sepsis

10.2.2       Sepsis Diagnostic Market- Bacterial sepsis

10.2.3       Sepsis Diagnostic Market- Others

Chapter 11       Sepsis Diagnostic Market Analysis by Region

11.1           Key Findings for Sepsis Diagnostic Market- By region

11.2           Overview

11.2.1       Global Sepsis Diagnostic Market Analysis, By Technology, 2019 – 2028

11.2.2       Global Sepsis Diagnostic Market Analysis, By Product, 2019 – 2028

11.2.3       Global Sepsis Diagnostic Market Analysis, By Diagnostic method, 2019 – 2028

11.2.4       Global Sepsis Diagnostic Market Analysis, By Pathogen, 2019 – 2028

11.3           Sepsis Diagnostic Market – North America

11.3.1       Overview

11.3.2       U.S.

11.3.3       Canada

11.3.4       Mexico

11.3.5       North America Market, By Technology

11.3.6       North America Market, By Product

11.3.7       North America Market, By Diagnostic method

11.3.8       North America Market, By Pathogen

11.4           Sepsis Diagnostic Market – Europe

11.4.1       Overview

11.4.2       Germany

11.4.3       United Kingdom

11.4.4       France

11.4.5       Italy

11.4.6       Rest Of Europe

11.4.7       Europe Market, By Technology

11.4.8       Europe Market, By Product

11.4.9       Europe market by, Diagnostic method

11.4.10     Europe Market, By Pathogen

11.5           Sepsis Diagnostic Market – Asia Pacific

11.5.1       Overview

11.5.2       China

11.5.3       Japan

11.5.4       India

11.5.5       Rest of APAC

11.5.6       Asia Pacific Market, By Technology

11.5.7       Asia Pacific Market, By Product

11.5.8       Asia Pacific Market, By Diagnostic method

11.5.9       Asia Pacific Market, By Pathogen

11.6           Sepsis Diagnostic Market – SAMEA

11.6.1       Overview

11.6.2       Middle East & Africa (MEA)

11.6.3       South America

11.6.4       Rest Of World

11.6.5       South America, Middle East and Africa Market, By Technology

11.6.6       South America, Middle East and Africa Market, By Product

11.6.7       South America, Middle East and Africa Market, By Diagnostic method

11.6.8       South America, Middle East and Africa Market, By Pathogen

Chapter 12       Market Competition Analysis

12.1           Market Share/Positioning Analysis

12.1.1       Market Positioning of Key Vendors, 2019

12.1.2       Key Strategies Adopted by the Leading Players

12.1.3       Recent Developments

Chapter 13       Company Profiles- Snapshot

13.1           bioMérieux SA

13.1.1       Business Fundamentals

13.1.2       Financial Snapshots

13.1.3       Product Portfolio

13.1.4       Recent Developments

13.2           Beckman Coulter, Inc.

13.3           Becton, Dickinson and Company

13.4           Sysmex Corporation

13.5           F. Hoffmann-La Roche AG

13.6           Thermo Fisher Scientific, Inc.

*More than 10 Companies are profiled in this Research Report*

*Financials would be provided on a best efforts basis for private companies”

Chapter 14       Appendix

 

 

 

Request for Sample

Please fill out the form to receive sample pages of the report